Exact Mass: 471.33484100000004
Exact Mass Matches: 471.33484100000004
Found 272 metabolites which its exact mass value is equals to given mass value 471.33484100000004
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Terfenadine
C32H41NO2 (471.31371260000003)
Terfenadine is only found in individuals that have used or taken this drug. In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.Terfenadine competes with histamine for binding at H1-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. This reversible binding of terfenadine to H1-receptors suppresses the formation of edema, flare, and pruritus resulting from histaminic activity. As the drug does not readily cross the blood-brain barrier, CNS depression is minimal. R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Terfenadine ((±)-Terfenadine) is a potent open-channel blocker of hERG with an IC50 of 204 nM[1]. Terfenadine, an H1 histamine receptor antagonist, acts as a potent apoptosis inducer in melanoma cells through modulation of Ca2+ homeostasis. Terfenadine induces ROS-dependent apoptosis, simultaneously activates Caspase-4, -2, -9[2].
Cervonyl carnitine
C29H45NO4 (471.33484100000004)
Cervonyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.) [HMDB] Cervonyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).
(10E,15Z)-9,12,13-Trihydroxyoctadeca-10,15-dienoylcarnitine
(10E,15Z)-9,12,13-trihydroxyoctadeca-10,15-dienoylcarnitine is an acylcarnitine. More specifically, it is an (10E,15Z)-9,12,13-trihydroxyoctadeca-10,15-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (10E,15Z)-9,12,13-trihydroxyoctadeca-10,15-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (10E,15Z)-9,12,13-trihydroxyoctadeca-10,15-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7Z,10Z,13Z,16Z,19Z)-Docosa-4,7,10,13,16,19-hexaenoylcarnitine
C29H45NO4 (471.33484100000004)
(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
methyl (Z)-N-13-docosenoylanthranilate|methyl N-Delta13-docosenoylanthranilate
N-(1,4-Dihydroxy-1,2,3,4-tetrahydronaphthyl)-propyl-N-diphenylmethyl-N-3,3-dimethylbutylamine
C32H41NO2 (471.31371260000003)
terfenadine
C32H41NO2 (471.31371260000003)
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Terfenadine ((±)-Terfenadine) is a potent open-channel blocker of hERG with an IC50 of 204 nM[1]. Terfenadine, an H1 histamine receptor antagonist, acts as a potent apoptosis inducer in melanoma cells through modulation of Ca2+ homeostasis. Terfenadine induces ROS-dependent apoptosis, simultaneously activates Caspase-4, -2, -9[2].
Sipeimine, 3-Ac
C29H45NO4 (471.33484100000004)
Origin: Plant; SubCategory_DNP: Steroidal alkaloids, Cevanine alkaloids
Ala Ile Ile Arg
C21H41N7O5 (471.31690160000005)
Ala Ile Leu Arg
C21H41N7O5 (471.31690160000005)
Ala Ile Arg Ile
C21H41N7O5 (471.31690160000005)
Ala Ile Arg Leu
C21H41N7O5 (471.31690160000005)
Ala Leu Ile Arg
C21H41N7O5 (471.31690160000005)
Ala Leu Leu Arg
C21H41N7O5 (471.31690160000005)
Ala Leu Arg Ile
C21H41N7O5 (471.31690160000005)
Ala Leu Arg Leu
C21H41N7O5 (471.31690160000005)
Ala Arg Ile Ile
C21H41N7O5 (471.31690160000005)
Ala Arg Ile Leu
C21H41N7O5 (471.31690160000005)
Ala Arg Leu Ile
C21H41N7O5 (471.31690160000005)
Ala Arg Leu Leu
C21H41N7O5 (471.31690160000005)
Ile Ala Ile Arg
C21H41N7O5 (471.31690160000005)
Ile Ala Leu Arg
C21H41N7O5 (471.31690160000005)
Ile Ala Arg Ile
C21H41N7O5 (471.31690160000005)
Ile Ala Arg Leu
C21H41N7O5 (471.31690160000005)
Ile Ile Ala Arg
C21H41N7O5 (471.31690160000005)
Ile Ile Ile Asn
C22H41N5O6 (471.30566860000005)
Ile Ile Lys Val
Ile Ile Leu Asn
C22H41N5O6 (471.30566860000005)
Ile Ile Asn Ile
C22H41N5O6 (471.30566860000005)
Ile Ile Asn Leu
C22H41N5O6 (471.30566860000005)
Ile Ile Gln Val
C22H41N5O6 (471.30566860000005)
Ile Ile Arg Ala
C21H41N7O5 (471.31690160000005)
Ile Ile Val Lys
Ile Ile Val Gln
C22H41N5O6 (471.30566860000005)
Ile Lys Ile Val
Ile Lys Leu Val
Ile Lys Val Ile
Ile Lys Val Leu
Ile Leu Ala Arg
C21H41N7O5 (471.31690160000005)
Ile Leu Ile Asn
C22H41N5O6 (471.30566860000005)
Ile Leu Lys Val
Ile Leu Leu Asn
C22H41N5O6 (471.30566860000005)
Ile Leu Asn Ile
C22H41N5O6 (471.30566860000005)
Ile Leu Asn Leu
C22H41N5O6 (471.30566860000005)
Ile Leu Gln Val
C22H41N5O6 (471.30566860000005)
Ile Leu Arg Ala
C21H41N7O5 (471.31690160000005)
Ile Leu Val Lys
Ile Leu Val Gln
C22H41N5O6 (471.30566860000005)
Ile Asn Ile Ile
C22H41N5O6 (471.30566860000005)
Ile Asn Ile Leu
C22H41N5O6 (471.30566860000005)
Ile Asn Leu Ile
C22H41N5O6 (471.30566860000005)
Ile Asn Leu Leu
C22H41N5O6 (471.30566860000005)
Ile Gln Ile Val
C22H41N5O6 (471.30566860000005)
Ile Gln Leu Val
C22H41N5O6 (471.30566860000005)
Ile Gln Val Ile
C22H41N5O6 (471.30566860000005)
Ile Gln Val Leu
C22H41N5O6 (471.30566860000005)
Ile Arg Ala Ile
C21H41N7O5 (471.31690160000005)
Ile Arg Ala Leu
C21H41N7O5 (471.31690160000005)
Ile Arg Ile Ala
C21H41N7O5 (471.31690160000005)
Ile Arg Leu Ala
C21H41N7O5 (471.31690160000005)
Ile Val Ile Lys
Ile Val Ile Gln
C22H41N5O6 (471.30566860000005)
Ile Val Lys Ile
Ile Val Lys Leu
Ile Val Leu Lys
Ile Val Leu Gln
C22H41N5O6 (471.30566860000005)
Ile Val Gln Ile
C22H41N5O6 (471.30566860000005)
Ile Val Gln Leu
C22H41N5O6 (471.30566860000005)
Lys Ile Ile Val
Lys Ile Leu Val
Lys Ile Val Ile
Lys Ile Val Leu
Lys Leu Ile Val
Lys Leu Leu Val
Lys Leu Val Ile
Lys Leu Val Leu
Lys Val Ile Ile
Lys Val Ile Leu
Lys Val Leu Ile
Lys Val Leu Leu
Leu Ala Ile Arg
C21H41N7O5 (471.31690160000005)
Leu Ala Leu Arg
C21H41N7O5 (471.31690160000005)
Leu Ala Arg Ile
C21H41N7O5 (471.31690160000005)
Leu Ala Arg Leu
C21H41N7O5 (471.31690160000005)
Leu Ile Ala Arg
C21H41N7O5 (471.31690160000005)
Leu Ile Ile Asn
C22H41N5O6 (471.30566860000005)
Leu Ile Lys Val
Leu Ile Leu Asn
C22H41N5O6 (471.30566860000005)
Leu Ile Asn Ile
C22H41N5O6 (471.30566860000005)
Leu Ile Asn Leu
C22H41N5O6 (471.30566860000005)
Leu Ile Gln Val
C22H41N5O6 (471.30566860000005)
Leu Ile Arg Ala
C21H41N7O5 (471.31690160000005)
Leu Ile Val Lys
Leu Ile Val Gln
C22H41N5O6 (471.30566860000005)
Leu Lys Ile Val
Leu Lys Leu Val
Leu Lys Val Ile
Leu Lys Val Leu
Leu Leu Ala Arg
C21H41N7O5 (471.31690160000005)
Leu Leu Ile Asn
C22H41N5O6 (471.30566860000005)
Leu Leu Lys Val
Leu Leu Leu Asn
C22H41N5O6 (471.30566860000005)
Leu Leu Asn Ile
C22H41N5O6 (471.30566860000005)
Leu Leu Asn Leu
C22H41N5O6 (471.30566860000005)
Leu Leu Gln Val
C22H41N5O6 (471.30566860000005)
Leu Leu Arg Ala
C21H41N7O5 (471.31690160000005)
Leu Leu Val Lys
Leu Leu Val Gln
C22H41N5O6 (471.30566860000005)
Leu Asn Ile Ile
C22H41N5O6 (471.30566860000005)
Leu Asn Ile Leu
C22H41N5O6 (471.30566860000005)
Leu Asn Leu Ile
C22H41N5O6 (471.30566860000005)
Leu Asn Leu Leu
C22H41N5O6 (471.30566860000005)
Leu Gln Ile Val
C22H41N5O6 (471.30566860000005)
Leu Gln Leu Val
C22H41N5O6 (471.30566860000005)
Leu Gln Val Ile
C22H41N5O6 (471.30566860000005)
Leu Gln Val Leu
C22H41N5O6 (471.30566860000005)
Leu Arg Ala Ile
C21H41N7O5 (471.31690160000005)
Leu Arg Ala Leu
C21H41N7O5 (471.31690160000005)
Leu Arg Ile Ala
C21H41N7O5 (471.31690160000005)
Leu Arg Leu Ala
C21H41N7O5 (471.31690160000005)
Leu Val Ile Lys
Leu Val Ile Gln
C22H41N5O6 (471.30566860000005)
Leu Val Lys Ile
Leu Val Lys Leu
Leu Val Leu Lys
Leu Val Leu Gln
C22H41N5O6 (471.30566860000005)
Leu Val Gln Ile
C22H41N5O6 (471.30566860000005)
Leu Val Gln Leu
C22H41N5O6 (471.30566860000005)
Asn Ile Ile Ile
C22H41N5O6 (471.30566860000005)
Asn Ile Ile Leu
C22H41N5O6 (471.30566860000005)
Asn Ile Leu Ile
C22H41N5O6 (471.30566860000005)
Asn Ile Leu Leu
C22H41N5O6 (471.30566860000005)
Asn Leu Ile Ile
C22H41N5O6 (471.30566860000005)
Asn Leu Ile Leu
C22H41N5O6 (471.30566860000005)
Asn Leu Leu Ile
C22H41N5O6 (471.30566860000005)
Asn Leu Leu Leu
C22H41N5O6 (471.30566860000005)
Gln Ile Ile Val
C22H41N5O6 (471.30566860000005)
Gln Ile Leu Val
C22H41N5O6 (471.30566860000005)
Gln Ile Val Ile
C22H41N5O6 (471.30566860000005)
Gln Ile Val Leu
C22H41N5O6 (471.30566860000005)
Gln Leu Ile Val
C22H41N5O6 (471.30566860000005)
Gln Leu Leu Val
C22H41N5O6 (471.30566860000005)
Gln Leu Val Ile
C22H41N5O6 (471.30566860000005)
Gln Leu Val Leu
C22H41N5O6 (471.30566860000005)
Gln Val Ile Ile
C22H41N5O6 (471.30566860000005)
Gln Val Ile Leu
C22H41N5O6 (471.30566860000005)
Gln Val Leu Ile
C22H41N5O6 (471.30566860000005)
Gln Val Leu Leu
C22H41N5O6 (471.30566860000005)
Arg Ala Ile Ile
C21H41N7O5 (471.31690160000005)
Arg Ala Ile Leu
C21H41N7O5 (471.31690160000005)
Arg Ala Leu Ile
C21H41N7O5 (471.31690160000005)
Arg Ala Leu Leu
C21H41N7O5 (471.31690160000005)
Arg Ile Ala Ile
C21H41N7O5 (471.31690160000005)
Arg Ile Ala Leu
C21H41N7O5 (471.31690160000005)
Arg Ile Ile Ala
C21H41N7O5 (471.31690160000005)
Arg Ile Leu Ala
C21H41N7O5 (471.31690160000005)
Arg Leu Ala Ile
C21H41N7O5 (471.31690160000005)
Arg Leu Ala Leu
C21H41N7O5 (471.31690160000005)
Arg Leu Ile Ala
C21H41N7O5 (471.31690160000005)
Arg Leu Leu Ala
C21H41N7O5 (471.31690160000005)
Arg Val Val Val
C21H41N7O5 (471.31690160000005)
Val Ile Ile Lys
Val Ile Ile Gln
C22H41N5O6 (471.30566860000005)
Val Ile Lys Ile
Val Ile Lys Leu
Val Ile Leu Lys
Val Ile Leu Gln
C22H41N5O6 (471.30566860000005)
Val Ile Gln Ile
C22H41N5O6 (471.30566860000005)
Val Ile Gln Leu
C22H41N5O6 (471.30566860000005)
Val Lys Ile Ile
Val Lys Ile Leu
Val Lys Leu Ile
Val Lys Leu Leu
Val Leu Ile Lys
Val Leu Ile Gln
C22H41N5O6 (471.30566860000005)
Val Leu Lys Ile
Val Leu Lys Leu
Val Leu Leu Lys
Val Leu Leu Gln
C22H41N5O6 (471.30566860000005)
Val Leu Gln Ile
C22H41N5O6 (471.30566860000005)
Val Leu Gln Leu
C22H41N5O6 (471.30566860000005)
Val Gln Ile Ile
C22H41N5O6 (471.30566860000005)
Val Gln Ile Leu
C22H41N5O6 (471.30566860000005)
Val Gln Leu Ile
C22H41N5O6 (471.30566860000005)
Val Gln Leu Leu
C22H41N5O6 (471.30566860000005)
Val Arg Val Val
C21H41N7O5 (471.31690160000005)
Val Val Arg Val
C21H41N7O5 (471.31690160000005)
Val Val Val Arg
C21H41N7O5 (471.31690160000005)
CAR 22:6
C29H45NO4 (471.33484100000004)
n-Hexadecyl-trimethyl-ammonium-3-hydroxy-2-naphthoate
tris(2-hydroxyethyl)ammonium hexadecyl sulphate
C22H49NO7S (471.32295640000007)
bis(2-ethylhexyl) hydrogen phosphate, compound with 2,2,2-nitrilotriethanol (1:1)
C22H50NO7P (471.33247200000005)
Sodium glycochenodeoxycholate
C26H42NNaO5 (471.2960522000001)
A bile acid salt that is the sodium salt of glycochenodeoxycholic acid. Glycochenodeoxycholic acid sodium salt (Chenodeoxycholylglycine sodium salt) is a bile acid formed in the liver from chenodeoxycholate and glycine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. Glycochenodeoxycholic acid sodium salt (Chenodeoxycholylglycine sodium salt) induces hepatocyte apoptosis[1][2].
Hederagenin(1-)
A monocarboxylic acid anion that is the conjugate base of hederagenin, obtained by deprotonation of the carboxy group; major species at pH 7.3.
Cochalate
A monocarboxylic acid anion resulting from the deprotonation of the carboxy group of cochalic acid. The major species at pH 7.3.
(10E,15Z)-9,12,13-Trihydroxyoctadeca-10,15-dienoylcarnitine
[3-carboxy-2-[(Z)-10-nitrooctadec-9-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(Z)-9-nitrooctadec-9-enoyl]oxypropyl]-trimethylazanium
Sodium glycodeoxycholate
C26H42NNaO5 (471.2960522000001)
A bile acid salt that is the sodium salt of glycodeoxycholic acid.
N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
C27H41N3O4 (471.30969060000007)
N-[(4S,7R,8S)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C27H41N3O4 (471.30969060000007)
N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
C27H41N3O4 (471.30969060000007)
N-[(4R,7R,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C27H41N3O4 (471.30969060000007)
N-[(4R,7S,8S)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C27H41N3O4 (471.30969060000007)
N-[(4R,7S,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C27H41N3O4 (471.30969060000007)
N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
C27H41N3O4 (471.30969060000007)
N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
C27H41N3O4 (471.30969060000007)
N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
C27H41N3O4 (471.30969060000007)
N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
C27H41N3O4 (471.30969060000007)
N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
C27H41N3O4 (471.30969060000007)
N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
C27H41N3O4 (471.30969060000007)
N-[(4S,7S,8S)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C27H41N3O4 (471.30969060000007)
N-[(4S,7R,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C27H41N3O4 (471.30969060000007)
N-[(4S,7S,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C27H41N3O4 (471.30969060000007)
21-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]henicosanoate
20-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxoicosanoate
(19R)-19-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxoicosanoate
(20R)-20-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxyhenicosanoate
(7Z,10Z,13Z,16Z,19Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]docosa-7,10,13,16,19-pentaenamide
(4Z,7Z,10Z,13Z,16Z,19Z)-N-(1,3-dihydroxyoctan-2-yl)docosa-4,7,10,13,16,19-hexaenamide
(5Z,8Z,11Z,14Z,17Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]icosa-5,8,11,14,17-pentaenamide
(3Z,6Z,9Z,12Z,15Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]octadeca-3,6,9,12,15-pentaenamide
(7Z,10Z,13Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]hexadeca-7,10,13-trienamide
(6Z,9Z,12Z,15Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]octadeca-6,9,12,15-tetraenamide
(4Z,7Z,10Z,13Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexadeca-4,7,10,13-tetraenamide
(4E,8E,12E)-3-hydroxy-2-(undecanoylamino)tetradeca-4,8,12-triene-1-sulfonic acid
C25H45NO5S (471.30182800000006)
(4E,8E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]dodeca-4,8-diene-1-sulfonic acid
C25H45NO5S (471.30182800000006)
(4E,8E,12E)-2-(decanoylamino)-3-hydroxypentadeca-4,8,12-triene-1-sulfonic acid
C25H45NO5S (471.30182800000006)
4-[3-acetyloxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
oscr#38(1-)
A hydroxy fatty acid ascaroside anion resulting from the deprotonation of the carboxy group of oscr#38. The conjugate base of oscr#38 and the major species at pH 7.3.
NA-2AAA 22:6(4Z,7Z,10Z,13Z,16Z,19Z)
C28H41NO5 (471.29845760000006)
1-{1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl}-3-{14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadecan-2-yl}propan-1-one
(1s,2s,7r,8s)-8-{2-[(1s,2r,3r,7r,10s,11r,13s,14r)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl]ethyl}-1,5-dimethyl-6-oxabicyclo[3.2.1]octane-2,7-diol
(1s,9r)-6-[(2s,5r,6r)-6-[(2e,4s,6r)-4,6-dimethyloct-2-en-2-yl]-5-methyloxan-2-yl]-1-hydroxy-4-methyl-8-oxa-4-azatricyclo[7.4.0.0²,⁷]trideca-2,6-diene-5,11-dione
C28H41NO5 (471.29845760000006)
(1s,2s,5s,7r,8s)-8-{2-[(1s,2r,3r,7r,10s,11r,13s,14r)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl]ethyl}-1,5-dimethyl-6-oxabicyclo[3.2.1]octane-2,7-diol
n-[2-(methoxycarbonyl)phenyl]docos-13-enimidic acid
2-methyl-6-(13-oxotetradecyl)piperidin-3-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate
C29H45NO4 (471.33484100000004)
2,3-dimethoxy-6-(10-methoxy-3,5,7,9,11,13-hexamethyltetradeca-2,5,7,11-tetraen-1-yl)-5-methylpyridin-4-ol
C29H45NO4 (471.33484100000004)
(1s,2r,3s,4s,5r)-5-[(2e)-but-2-en-2-yl]-4-[(3e,6e)-8-(4-hydroxy-5,6-dimethoxy-3-methylpyridin-2-yl)-6-methylocta-1,3,6-trien-2-yl]-1,3-dimethylcyclopentane-1,2-diol
C28H41NO5 (471.29845760000006)
6-[6-(4,6-dimethyloct-2-en-2-yl)-5-methyloxan-2-yl]-1-hydroxy-4-methyl-8-oxa-4-azatricyclo[7.4.0.0²,⁷]trideca-2,6-diene-5,11-dione
C28H41NO5 (471.29845760000006)
(1s,9r)-6-[(2s,5r,6r)-6-[(2e,4r,6s)-4,6-dimethyloct-2-en-2-yl]-5-methyloxan-2-yl]-1-hydroxy-4-methyl-8-oxa-4-azatricyclo[7.4.0.0²,⁷]trideca-2,6-diene-5,11-dione
C28H41NO5 (471.29845760000006)
(13z)-n-[2-(methoxycarbonyl)phenyl]docos-13-enimidic acid
(1s,9r)-6-[(2s,5r,6r)-6-[(2e)-4,6-dimethyloct-2-en-2-yl]-5-methyloxan-2-yl]-1-hydroxy-4-methyl-8-oxa-4-azatricyclo[7.4.0.0²,⁷]trideca-2,6-diene-5,11-dione
C28H41NO5 (471.29845760000006)
2-[(2e,5e,7e,9r,10r)-10-[(2s)-3-[(2e)-but-2-en-2-yl]-2-methyloxiran-2-yl]-10-hydroxy-3,7,9-trimethyldeca-2,5,7-trien-1-yl]-5,6-dimethoxy-3-methylpyridin-4-ol
C28H41NO5 (471.29845760000006)
2-methyl-6-(13-oxotetradecyl)piperidin-3-yl 3-(4-hydroxyphenyl)prop-2-enoate
C29H45NO4 (471.33484100000004)
1-[(1r,4r,5s)-1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl]-3-[(1s,2r,3r,7s,10s,13s,14r)-14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadecan-2-yl]propan-1-one
2,3-dimethoxy-6-[(2e,5e,7e,9s,10s,11e)-10-methoxy-3,5,7,9,11,13-hexamethyltetradeca-2,5,7,11-tetraen-1-yl]-5-methylpyridin-4-ol
C29H45NO4 (471.33484100000004)